call Roche seemed more cautious than previously around the Avastin combo opportunity. Beyond PD-L1, phase II ROMULUS data for the Anti-79b in NHL (Non-Hodgkin's lymphoma) also at ASCO (May 31) should provide another leg to Roche's existing growth and protection strategies for the Rituxan franchise (which cu